Nanotechnology in Pharmaceuticals and Biotech Conference:
Conference Background
An increasing use of nanotechnology by the pharmaceutical and biotechnology industries is widely anticipated – the global market for medical nanotechnology is expected to be more than $3 billion in 5 years. Currently 61 nanotech-based drugs and delivery systems and 91 devices or diagnostic tests have entered preclinical, clinical, or commercial development.
This two-day conference will bring together key decision makers and international experts in the field of nanotechnology. Delegates and speakers will come from pharmaceutical companies and technology providers using nanotechnology for drug discovery, development, delivery and nanomedicine.
TO BOOK A PLACE AT THIS CONFERENCE
PLEASE CALL VISIONGAIN ON +44 (0)20 8767 6711
Why should you attend?
Visiongain’s Nanotechnology in Pharmaceuticals & Biotech conference will focus on the commercial applications of nanotechnology as it applies to pharma/biotech:
Drug Delivery: learn how nanotechnology will benefit the different delivery formats - injectable, oral, implantable, transdermal, etc.
Drug Discovery: examine the potential of different nanotechnology-based tools for improving imaging, screening and research techniques, including nanolithography, nanoarrays and mass spectrometry
Drug Development: discover the advantages of nanoparticle formulations for resolving solubility issues and increasing the number of compounds available for potential development
Diagnostics: find out how quantum dots can be used to tag biological targets of choice
Therapeutics: determine the potential of nano-based compounds for targeting tumours and cancers
Commercialisation Strategies: hear from leading pharma executives and management consultants on how to successfully develop your nanobusiness
Who should attend?
Companies
Pharmaceutical & Biotechnology Companies
Nanotechnology Companies
Medical Device & Diagnostic Companies
Drug Regulators, Healthcare Agencies, Government Departments
Investment Banks, Venture Capitalists
Solicitors
Consultants
Job Titles
Directors, Heads and managers of:
Strategic Planning
New Product Development
Business Development
R&D
Research Engineer
Laboratory Heads
Scientific Affairs
Principal Scientist
Chief Scientific Officer
Biomaterials
Marketing
(IP/Patent) Counsel
Business Operations
Project Management
Key Speakers
Dr. Jianling Wang, Head eADME Programme, Novartis Institute for Biomedical research
Steve Ellul, Director, Business Development, Eurand Pharmaceuticals
Dr. Stephen Barry, President, Alnis BioSciences
David Manser, Scientist, Elan Drug Technology
Dr. Barrett E. Rabinow, Director of Strategic Development, Baxter Healthcare
Dr. Donald A. Tomalia, President and Chief Technology Officer, Dendritic Nanotechnologies
Edward K. Moran, Leader, Nanotechnology Industry Practice, Deloitte Services
Ottilia Saxl, CEO, Institute of Nanotechnology
Dr. Colin Brenan, Chief Technology Officer, BioTrove
Conference Workshop
24 April 2006
Commercialising nanotechnology and alliance management
Led By: Barrett E. Rabinow, Senior Director, Baxter Healthcare Corporation
Malcolm Wilkinson, Managing Director, Technology for Industry
|
